Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 203

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Reducing the Risk for Transplantation-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: How Much Progress Has Been Made?

Open access
Horan, John T., Logan, Brent R., Agovi-Johnson, Manza-A., Lazarus, Hillard M., Bacigalupo, Andrea A., Ballen, Karen K., Bredeson, Christopher N., Carabasi, Matthew H., Gupta, Vikas, Hale, Gregory A., Khoury, Hanna Jean, Juckett, Mark B., Litzow, Mark R., Martino, Rodrigo, McCarthy, Philip L., Smith, Franklin O., Rizzo, J. Douglas, Pasquini, Marcelo C. · 2011 · Journal of Clinical Oncology

Abstract

Purpose: Transplantation-related mortality (TRM) is a major barrier to the success of allogeneic hematopoietic cell transplantation (HCT). Patients and Methods: We assessed changes in the incidence of TRM and overall survival from 1985 through 2004 in 5,972 patients younger than age 50 years who received myeloablative conditioning and HCT for acute myeloid leukemia (AML) in first complete remission (CR1) or second complete remission (CR2). Results: Among HLA-matched sibling donor transplantation recipients, the relative risks (RRs) for TRM were 0.5 and 0.3 for 2000 to 2004 compared with those for 1985 to 1989 in patients in CR1 and CR2, respectively (P < .001). The RRs for all causes of mortality in the latter period were 0.73 (P = .001) and 0.60 (P = .005) for the CR1 and CR2 groups, respectively. Among unrelated donor transplantation recipients, the RRs for TRM were 0.73 (P = .095) and 0.58 (P < .001) for 2000 to 2004 compared with those in 1990 to 1994 in the CR1 and CR2 groups, respectively. Reductions in mortality were observed in the CR2 group (RR, 0.74; P = .03) but not in the CR1 group. Conclusion: Our results suggest that innovations in transplantation care since the 1980s and 1990s have reduced the risk of TRM in patients undergoing allogeneic HCT for AML and that this reduction has been accompanied by improvements in overall survival.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2010.32.5001

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 203

Metadata

Authors
Horan, J. T., Logan, B. R., Agovi-Johnson, M.-A., Lazarus, H. M., Bacigalupo, A. A., Ballen, K. K., Bredeson, C. N., Carabasi, M. H., Gupta, V., Hale, G. A., Khoury, H. J., Juckett, M. B., Litzow, M. R., Martino, R., McCarthy, P. L., Smith, F. O., Rizzo, J. D., & Pasquini, M. C.
Venue
Journal of Clinical Oncology
Published
2011-03-01
Volume
29
Issue
7
Pages
805-813
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2128428511
Cited by
203
References
1
FWCI
8.11
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reducing the Risk for Transplantation-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: How Much Progress Has Been Made? https://app.cochat.ai/papers/10.1200/jco.2010.32.5001
The paper
Horan, J. T., Logan, B. R., Agovi-Johnson, M.-A., Lazarus, H. M., Bacigalupo, A. A., Ballen, K. K., Bredeson, C. N., Carabasi, M. H., Gupta, V., Hale, G. A., Khoury, H. J., Juckett, M. B., Litzow, M. R., Martino, R., McCarthy, P. L., Smith, F. O., Rizzo, J. D., & Pasquini, M. C. (2011). Reducing the Risk for Transplantation-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: How Much Progress Has Been Made? Journal of Clinical Oncology. https://doi.org/10.1200/jco.2010.32.5001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.